New York, NY, May 27, 2015 --(PR.com
)-- In earlier time, Creative Diagnostics together with Creative Biolabs developed a unique bacterial display technology, Hi-affinityTM, for the development of human antibodies with pM affinity, intended for research, diagnostic and therapeutic use.
“With the emerging of this technology, an in vitro antibody production technology with highest affinity is available.” The CSO of Creative Diagnostics said so.
Today, Creative Diagnostics' the Hi-affinity™ Bacterial Display Platform is further developed by utilizing a unique antibody selection process that relies on the natural twin-arginine translocation (Tat) system in E. coli. Compared to conventional phage display technologies, Hi-affinity™ is less dependent on the Sec translocation pathway by exploiting the properties of the Tat pathway which only exports folded proteins that have already attained their native conformation in the cytoplasm.
For the Hi-affinityTM derived antibodies, customers have the exclusive rights to the antibodies including the antibody CDR sequence and any information generated by the customer through using the antibodies.
For more information, please visit www.creative-diagnostics.com/Hi-affinity-Bacterial-Display-Platform-for-Creating-Therapeutic-Antibodies.html.
About Creative Diagnostics Hi-affinity™
Hi-affinityTM human scFv antibody library is created by combining a highly diverse collection of synthetically-constructed randomized CDR sequences that are further diversified by random lengths using a unique proprietary technique.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market.
About Creative Biolabs
Creative Biolabs is a leading custom service provider that has extensive experience in various antibody production and engineering fields. Its service portfolio includes mouse and rat monoclonal antibody production using hybridoma technology, human, monkey, rabbit, chicken, dog, llama and camel monoclonal antibody production using various antibody library technologies.